4.5 Article

Predicting Aggressive Decline in Mild Cognitive Impairment The Importance of White Matter Hyperintensities

期刊

JAMA NEUROLOGY
卷 71, 期 7, 页码 872-877

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2014.667

关键词

-

资金

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. Department of Defense ADM [W81XWH-12-2-0012]
  3. National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering
  4. Alzheimers Association
  5. Alzheimer's Drug Discovery Foundation
  6. BioClinica Inc
  7. Biogen Idec Inc
  8. Bristol-Myers Squibb Co
  9. Eisai Inc
  10. Elan Pharmaceuticals Inc
  11. Eli Lilly and Co
  12. F. Hoffmann La Roche Ltd and its affiliated company Genentech Inc
  13. GE Healthcare
  14. Innogenetics NV
  15. IXICO Ltd
  16. Janssen Alzheimer Immunotherapy Research & Development LLC
  17. Johnson & Johnson Pharmaceutical Research & Development LLC
  18. Medpace Inc
  19. Merck Co Inc
  20. Mesa Scale Diagnostics LLC
  21. NeuroRx Research
  22. Novartis Pharmaceuticals Corp
  23. Pfizer Inc
  24. Piramal Imaging
  25. Servier
  26. Synarc Inc
  27. Takeda Pharmaceutical Co.
  28. Canadian Institutes of Health Research
  29. Northern California Institute for Research and Education

向作者/读者索取更多资源

IMPORTANCE Although white matter hyperintensities (WMHs) are associated with the risk for Alzheimer disease, it is unknown whether they represent an independent source of impairment or interact with known markers of disease. OBJECTIVE To examine the degree to which WMHs predict aggressive cognitive decline among individuals with mild cognitive impairment, either independently or by modifying the effects of entorhinal cortex volume (ECV), a marker of Alzheimer disease-related neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS The Alzheimer's Disease Neuroimaging Initiative is a longitudinal study with 6-month follow-up visits. Three hundred thirty-two participants (mean [SD] age, 74.6 [7.4] years; 118 women) of a total of 374 participants diagnosed as having mild cognitive impairment were included. Participants were excluded if they did not have longitudinal data, apolipoprotein E genotype data, or had evidence of supratentorial infarct. MAIN OUTCOMES AND MEASURES A decline in Mini-Mental State Examination score of 3 points over 6 months or 6 points over 1 year between consecutive visits was defined as aggressive decline. White matter hyperintensity volume and ECV were entered as predictors in Cox proportional hazards models and Wilcoxon-Breslow tests to examine their impact on this outcome, adjusting for sex, age, education, and apolipoprotein E status. RESULTS Greater WMH volume at baseline, apolipoprotein E epsilon 4 status, and smaller ECV at baseline were associated with an increased risk for aggressive decline (hazard ratio [HR], 1.23; 95% CI, 1.05-1.43; P = .01 for WMH volume; HR, 1.49; 95% CI, 1.09-2.05; P = .04 for apolipoprotein E epsilon 4 status; HR, 0.66; 95% CI, 0.55-0.79; P < .001 for ECV). White matter hyperintensity volume modified the effect of ECV on aggressive decline risk: individuals with high ECV and low WMH were at particularly low likelihood of decline (chi(2) = 15, P = .001). Participants with Mini-Mental State Examination scores that declined by 3 or more points over 6 months or 6 or more points over 12 months were more likely to have converted to Alzheimer disease by the end of the follow-up period (chi(2) = 82, P < .001). CONCLUSIONS AND RELEVANCE White matter hyperintensity burden and ECV predict rapid cognitive decline among individuals with mild cognitive impairment both additively and multiplicatively.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据